Bayer completes $1.1bn Conceptus buy
This article was originally published in Scrip
Bayer has completed its $1.1bn acquisition of Conceptus, a US firm that developed and markets the Essure birth control method. The deal was announced last month (scripintelligence.com, 9 May 2013).
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.